Considerations for single- versus multiple-drug pharmacotherapy in the management of painful diabetic neuropathy. (2nd November 2021)

• Record Type: Journal Article
• Authors: Pafili, Kalliopi; Papanas, Nikolaos
• Is Part Of: Expert opinion on pharmacotherapy. Volume 22:Number 16(2021)
• Page Start: 2267
• Page End: 2280
• Publication Date: 2021-11-02
• Subjects: combination therapy -- diabetic peripheral neuropathy -- monotherapy -- neuropathic pain -- treatment; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2021.1909570
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: The efficacy of monotherapy to reduce pain from diabetic peripheral neuropathy (DPN) is frequently not satisfactory and guidelines do not provide unanimous treatment options. In this context, multiple drug pharmacotherapy may provide benefit. Areas covered: The aim of the present review is to describe the clinical trials addressing the pharmacotherapy of painful DPN. Studies discussing efficacy and tolerability of pharmacological agents that were assessed in monotherapy and in combination treatment are reported and discussed. Expert opinion: Several clinical trials have reported benefit of multiple-drug pharmacotherapy. Nevertheless, untoward effects of combination treatment are of concern. Importantly, some trials were restricted to comparison with placebo and other compared only with active comparator(s). Only limited clinical trials assessed selected cohorts of individuals experiencing different stages of painful DPN. Despite current limitations, some evidence of studies implicating a comparison to all active comparators points to safety and effectiveness of the combination of oxycodone with pregabalin and that of pregabalin with the 5% lidocaine plaster but future, clear-cut studies are required to drive evidence-based decisions in the clinical setting.